Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers

被引:14
|
作者
Lee, YC
Wu, CT
Shih, JY
Jou, YS
Chang, YL [1 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Pathol, Coll Med, Taipei 100, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan
[3] Natl Taiwan Univ, Coll Med, Taipei 100, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan
[5] Natl Hlth Res Inst, Div Mol & Genom Med, Taipei, Taiwan
关键词
FHIT; loss of heterozygosity; lung cancers;
D O I
10.1038/sj.bjc.6601778
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The fragile histidine triad (FHIT) gene, encompassing the FRA3B fragile site at chromosome 3p14.2, is a tumour suppressor gene involved in different tumour types including non-small-cell lung cancers (NSCLCs). In the current study, we examined for allelic deletion at the FHIT locus in 58 primary and microdissected NSCLCs, for which a clinicopathologic profile was available. We found a loss of 87.7% in heterozygosity (LOH) frequency at one or more microsatellite markers (D3S1289, D3S2408, D3S1766, D3S1312, D3S1600). Allelic deletion of D3S1766 was related to tumour histology in 10 of 11 squamous cell carcinomas (90.9%) displaying LOH compared with nine of 17 adenocarcinomas (52.9%; P = 0.049). Besides, in the subset of adenocarcinomas, a higher rate of LOH at D3S1289 was observed in male ( six out of eight, 75%) than in female patients (four out of 17, 23.5%; P = 0.028). However, FHIT LOH was not correlated overall with a variety of clinical parameters including sex, smoking status, staging, lymph node metastasis and survival. These results indicated that the high frequency of FHIT gene disruption was important in the development of both squamous cell carcinomas and adenocarcinomas. Furthermore, there was no association between LOH at FHIT and protein expression, suggesting the presence of complex mechanisms of Fhit inactivation. On the other hand, the association between FHIT LOH and p53 protein overexpression assessment reached statistical significance ( P = 0.026), implying that common alterations affect the two genes in tumour progression.
引用
收藏
页码:2378 / 2383
页数:6
相关论文
共 50 条
  • [41] p53 and angiogenesis in non-small-cell lung cancerReply to the letter from Giatromanolaki and Koukourakis
    G Fontanini
    British Journal of Cancer, 1998, 77 : 851 - 852
  • [42] ABERRATIONS OF THE P53 TUMOR SUPPRESSOR GENE IN HUMAN NON-SMALL-CELL CARCINOMAS OF THE LUNG
    KISHIMOTO, Y
    MURAKAMI, Y
    SHIRAISHI, M
    HAYASHI, K
    SEKIYA, T
    CANCER RESEARCH, 1992, 52 (17) : 4799 - 4804
  • [43] In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer
    Jose Antonio Perdomo
    Yoshio Naomoto
    Minoru Haisa
    Toshiyoshi Fujiwara
    Madoka Hamada
    Yasuo Yasuoka
    Noriaki Tanaka
    Journal of Cancer Research and Clinical Oncology, 1998, 124 : 10 - 18
  • [44] p53 gene aberrations in non-small-cell lung carcinomas from a smoking population
    Liloglou, T
    Ross, H
    Prime, W
    Donnelly, RJ
    Spandidos, DA
    Gosney, JR
    Field, JK
    BRITISH JOURNAL OF CANCER, 1997, 75 (08) : 1119 - 1124
  • [45] Terminal differentiation in a non-small-cell bronchopulmonary carcinoma correlates with increased expression of p53
    Liscia, E
    Riou, D
    Siavoshian, S
    Boesch, S
    Lebert, V
    Tomasoni, C
    Dabouis, G
    Biard, JF
    Roussakis, C
    ANTICANCER RESEARCH, 1996, 16 (3A) : 1209 - 1212
  • [46] p53 gene aberrations in non-small-cell lung carcinomas from a smoking population
    T Liloglou
    H Ross
    W Prime
    RJ Donnelly
    DA Spandidos
    JR Gosney
    JK Field
    British Journal of Cancer, 1997, 75 : 1119 - 1124
  • [47] P53 EXPRESSION IN NON-SMALL-CELL LUNG-CANCER - CLINICAL AND BIOLOGICAL CORRELATIONS
    FONTANINI, G
    BIGINI, D
    VIGNATI, S
    MACCHIARINI, P
    PEPE, S
    ANGELETTI, CA
    PINGITORE, R
    SQUARTINI, F
    ANTICANCER RESEARCH, 1993, 13 (03) : 737 - 742
  • [48] In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer
    Perdomo, JA
    Naomoto, Y
    Haisa, M
    Fujiwara, T
    Hamada, M
    Yasuoka, Y
    Tanaka, N
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1998, 124 (01) : 10 - 18
  • [49] Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer
    Burke, L
    Khan, MA
    Freedman, AN
    Gemma, A
    Rusin, M
    Guinee, DG
    Bennett, WP
    Caporaso, NE
    Fleming, MV
    Travis, WD
    Colby, TV
    Trastek, V
    Pairolero, PC
    Tazelaar, HD
    Midthun, DE
    Liotta, LA
    Harris, CC
    CANCER RESEARCH, 1998, 58 (12) : 2533 - 2536
  • [50] Identification of expression signatures for non-small-cell lung carcinoma subtype classification
    Su, Ran
    Zhang, Jiahang
    Liu, Xiaofeng
    Wei, Leyi
    BIOINFORMATICS, 2020, 36 (02) : 339 - 346